Arcturus Therapeutics to Focus on Rare Diseases After COVID Vaccine Approval

Arcturus Therapeutics is refocusing on rare disease mRNA pipeline after gaining COVID-19 vaccine approvals in over 30 countries. CEO Joe Payne highlighted the company's LUNAR lipid nanoparticle delivery technology and manufacturing capabilities as differentiators. Arcturus is developing ARCT-810 for ornithine transcarbamylase (OTC) deficiency, with plans to discuss the regulatory path for pediatric use with the FDA in Q2. The pediatric population represents the highest unmet need and commercial opportunity within OTC deficiency.